KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Treasury Shares (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Treasury Shares for 12 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 29.86% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Dec 2025, up 29.86%, and an annual FY2025 reading of $4.6 million, up 29.86% over the prior year.
  • Treasury Shares was $3.2 million for Q4 2014 at Travere Therapeutics, roughly flat from $3.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.6 million in Q4 2025 and bottomed at $1.5 million in Q4 2021.
  • Average Treasury Shares over 5 years is $3.0 million, with a median of $2.9 million recorded in 2023.
  • Peak annual rise in Treasury Shares hit 235.85% in 2014, while the deepest fall reached 235.85% in 2014.
  • Year by year, Treasury Shares stood at $957272.0 in 2013, then skyrocketed by 235.85% to $3.2 million in 2014.
  • Business Quant data shows Treasury Shares for TVTX at $4.6 million in Q4 2025, $3.5 million in Q4 2024, and $2.9 million in Q4 2023.